-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Candel Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2020 to Q2 2025.
- Candel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was -$4.8M, a 78.4% increase year-over-year.
- Candel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was -$22.1M, a 55.7% increase year-over-year.
- Candel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$55.2M, a 45.4% decline from 2023.
- Candel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$37.9M, a 102% decline from 2022.
- Candel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.8M, a 48% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)